STAB

Statera Biopharma, Inc.

0.00 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.18% of the previous 17 February’s closed higher than January.

About Statera Biopharma, Inc.

Statera BioPharma, Inc. develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (Stat-401), and COVID-19 (stat-205) as well as expanding into fibromyalgia and multiple sclerosis.